RAS: Past, Present, and Future

RAS: Past, Present, and Future

1st Edition - January 29, 2022

Write a review

  • Editors: John O'Bryan, Gary Piazza
  • Hardcover ISBN: 9780128244852
  • eBook ISBN: 9780128244869

Purchase options

Purchase options
Available
DRM-free (PDF, EPub)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once “undruggable” RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.

Key Features

  • Overview of the history and development of efforts to pharmacologically inhibit RAS.
  • Discussion of the biochemistry and biology of different RAS mutant proteins and how this might be effectively leveraged in the development of anti-RAS therapies.
  • Up-to-date reviews of the cutting-edge approaches to develop new anti-RAS pharmacologics.

Readership

Basic scientists, clinicians, students and postdoctoral fellows with an interest in cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Contributors
  • Preface
  • Chapter One: A brief history of RAS and the RAS Initiative
  • Abstract
  • 1: Discovery of v-Ha-RAS, v-Ki-RAS and N-RAS
  • 2: Discovery of GAPs
  • 3: Discovery of RAS GEFs
  • 4: Discovery of RAF kinases and their relationship to RAS
  • 5: The RAS Initiative at Frederick National Laboratories
  • References
  • Chapter Two: Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations
  • Abstract
  • 1: Introduction
  • 2: RAS mutational frequencies in cancer
  • 3: RAS mutational frequencies across cancer
  • 4: All RAS mutant proteins are not equal
  • 5: RAS effector interactions and mutational frequencies
  • 6: Intrinsic nucleotide (GDP and GTP) dissociation and GTP hydrolysis
  • 7: GEFs and GAPs
  • 8: Conclusions
  • Acknowledgments
  • References
  • Chapter Three: Drug targeting opportunities en route to Ras nanoclusters
  • Abstract
  • 1: Introduction
  • 2: Ras processing and trafficking
  • 3: Trafficking-factors and -chaperones of Ras
  • 4: Organization of Ras in specific plasma membrane lipid domains and nanocluster
  • 5: Lipid domain and Ras nanocluster modulating factors
  • 6: Concluding remarks
  • References
  • Chapter Four: Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
  • Abstract
  • 1: Introduction
  • 2: KRAS: The predominant RAS gene mutated in human cancer
  • 3: Targeting KRAS for cancer treatment: Direct inhibition of RAS
  • 4: Targeting KRAS for cancer treatment: A focus on RAS effector signaling
  • 5: The ERK MAPK signaling network
  • 6: ERK feedback inhibition and the Goldilock Principle: A “just right” level of ERK signaling supports cancer growth
  • 7: Inhibition of the RAF-MEK-ERK cascade: Promises and challenges
  • 8: ERK regulation of a diverse phosphoproteome and transcriptome
  • 9: MYC: The critical determinant for ERK-dependent cancer growth?
  • 10: KRAS, ERK, MYC and metabolism: An Achilles heel for KRAS-mutant PDAC?
  • References
  • Chapter Five: Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
  • Abstract
  • 1: Introduction
  • 2: PAN-RAS inhibitors
  • 3: Discussion
  • 4: Conclusion
  • References
  • Chapter Six: Targeting RAS oncogenesis with SOS1 inhibitors
  • Abstract
  • 1: Introduction: RAS proteins and their Guanine Nucleotide Exchange Factors (GEFs)
  • 2: SOS1 as a molecular target for cancer therapy
  • 3: Discovery of the hydrophobic pocket on SOS1
  • 4: More binders for the hydrophobic pocket
  • 5: The long way from activators to inhibitors
  • 6: Molecular basis for SOS1 activation versus inhibition
  • 7: Selectivity against SOS2 and other RasGEFs
  • 8: Activity of SOS1 inhibitors in cellular assays
  • 9: SOS1 inhibition affects RAS mutations with residual intrinsic GTPase activity
  • 10: SOS1 inhibitors in RASopathies
  • 11: SOS1 inhibitors in combination therapy
  • 12: Clinical studies
  • 13: Conclusions
  • References
  • Chapter Seven: Inhibition of SHP2 as an approach to block RAS-driven cancers
  • Abstract
  • 1: Introduction
  • 2: Biology of RTK/RAS signaling
  • 3: General understanding of RAS-driven cancer and treatment
  • 4: The biological and oncogenic role of SHP2
  • 5: SHP2 inhibitors as potential therapies in RAS-driven cancers
  • 6: Conclusions and perspectives
  • References
  • Chapter Eight: Targeting the “undruggable” RAS with biologics
  • Abstract
  • 1: Introduction
  • 2: Anti-RAS biologics
  • 3: Targeting RAS using peptide-PROTACs: A new frontier for RAS inhibition
  • 4: Conclusion and future outlook
  • References
  • Chapter Nine: Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
  • Abstract
  • 1: Introduction
  • 2: Glycolysis
  • 3: Mitochondrial signaling and dynamics
  • 4: Autophagy
  • 5: Lipid scavenging and metabolism
  • 6: Macropinocytosis
  • 7: Concluding remarks
  • Acknowledgments
  • References
  • Chapter Ten: The RASopathies: Biology, genetics and therapeutic options
  • Abstract
  • 1: Introduction
  • 2: Neurofibromatosis type 1 (NF1) and related syndromes
  • 3: Legius syndrome
  • 4: Noonan syndrome and related syndromes
  • 5: Noonan-related syndromes
  • 6: Costello syndrome
  • 7: Cardiofaciocutaneous syndrome
  • 8: Gingival fibromatosis
  • 9: Capillary malformation-arteriovenous malformation syndrome
  • 10: Future directions
  • References

Product details

  • No. of pages: 356
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: January 29, 2022
  • Imprint: Academic Press
  • Hardcover ISBN: 9780128244852
  • eBook ISBN: 9780128244869

About the Serial Volume Editors

John O'Bryan

John O'Bryan
Dr. O'Bryan received his Ph.D. from the University of North Carolina at Chapel Hill. He then pursued postdoctoral studies at the Samuel Lunenfeld Institute in Toronto, Canada and the University of North Carolina at Chapel Hill. Dr. O'Bryan then established his independent research program at the National Institute of Environmental Health Science, NIH in Research Triangle Park before being recruited to the University of Illinois at Chicago. In 2018, he was recruited to the NCI-Designated Hollings Cancer Center at MUSC where he is Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics and Director of Graduate Studies. In addition, Dr. O'Bryan has a joint appointment as a Research Health Scientist at the Ralph H. Johnson VA Medical Center. Dr. O’Bryan’s research interests have centered on understanding the regulation of cell signaling pathways involved in normal and pathophysiological conditions, particularly cancer. His current research is focused on defining vulnerabilities in RAS that can be exploited for the development of new therapeutics for the treatment of RAS mutant cancers. His research is supported by grants from the National Institutes of Health, the Veterans Administration, and various private foundations.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, and Research Health Scientist, Ralph H. Johnson VA Medical Center, South Carolina USA

Gary Piazza

Gary Piazza
Dr. Piazza received his Ph.D. from The University of Alabama at Birmingham in 1986 and pursued postdoctoral studies at the Fox Chase Cancer Center and later at Brown University. Dr. Piazza also gained research experience in the pharmaceutical industry with the Proctor and Gamble Company and later with Cell Pathways Inc. Dr. Piazza returned to academic research in 2001 as the Director of Pharmacology at the Institute for Drug Development in San Antonio and later as a Principal Scientist at Southern Research in Birmingham where he established an independent research program funded by the NCI. In 2011, Dr. Piazza joined the University of South Alabama Mitchell Cancer Institute to hold the appointments of Professor of Oncologic Sciences and Pharmacology; Leader, Chemoprevention and Experimental Therapeutics; and Chief of the Drug Discovery Research Center up until 2021. Currently Dr. Piazza serves as the Head of the Department of Drug Discovery and Development and as Director of the Cancer Research Center in the Harrison School of Pharmacy at Auburn University. His research interests are in the field of cancer drug discovery. His research team has discovered and developed several promising drug candidates including a novel class of pan-RAS inhibitors with high potency and selectivity for cancer cells harboring mutant RAS. Dr. Piazza has been continuously funded by the NIH since 2004 and is a co-founder of ADT Pharmaceuticals LLC in Alabama.

Affiliations and Expertise

W.W. Walker Endowed Professor, Department Head, Drug Discovery and Development , Director, Harrison School of Pharmacy Cancer Research Center, Auburn University, Auburn, AL, USA

Ratings and Reviews

Write a review

There are currently no reviews for "RAS: Past, Present, and Future"